3.1.10. immunosuppression kidney transplantation. principle underlying successful immunosuppression ‘the balance survival’. practitioners must prescribe dosage drug high enough suppress rejection without endangering recipient’s health. increased understanding immune rejection led development safe modern immune suppression agents , suppress sensitised lymphocyte activity transplant. immunosuppression particularly important initial post-transplant period high incidence early post-transplant rejection. later post-operative stages, ‘graft adaptation‘ occurs, resulting low rejection rates seen maintenance patients. rejection prophylaxis therefore reduced time steroid tapering gradual lowering calcineurin inhibitor (cni) [243-245]. non-specific side effects immunosuppression include higher risk malignancy infection, particularly opportunistic infections [243-245]. immunosuppressants also dose-dependent specific side effects. current immunosuppressive protocols aim reduce drug-specific side effects using synergistic regimen. truly synergistic regimen allows profound dose reductions immunosuppressive drugs; therefore, reducing side effects whilst still maintaining efficacy due synergistic effects immunosuppressants. currently recommended standard initial immunosuppression regime provides excellent efficacy good tolerability [243-246]. given patients consists of: calcineurin inhibitors (preferably tacrolimus, alternatively cyclosporine);mycophenolate (mmf enteric-coated mycophenolate sodium [ec-mps]);steroids (prednisolone methylprednisolone);induction therapy (preferably basiliximab low standard risk patients anti-thymocyte globulin (atg) high-risk patients). multidrug regimen reflects current standard care majority transplant recipients worldwide [243-245] may modified according local needs immunological risk. standard regimen likely change new immunosuppressive drugs new treatment regimens developed [243-245]. addition, initial drug regimen need tailored individual needs patient suggested appearance side effects, lack efficacy protocol-driven requirements. recommendationstrength ratingperform initial rejection prophylaxis combination therapy calcineurin inhibitor (preferably tacrolimus), mycophenolate, steroids induction agent (either basiliximab anti-thymocyte globulin).strong